Anesthesia; Bariatric SurgeryPhase 4NCT03099616
Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Bariatric Surgery
A Phase 4 study testing Propofol and Desflurane in people with Anesthesia; Bariatric Surgery, run by Dr Nitin Sethi at 1 site in India.
Trial summary
Complete recovery from anaesthesia is absolutely desirable in the obese patients to avoid postoperative airway, oxygen ventilation or sleep apnea related complications. Over the years, Desflurane has emerged as the anaesthetic agent of choice for maintenance of anaesthesia in obese patients for its efficient… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Anesthesia; Bariatric Surgery
- What is being tested?
- Propofol and Desflurane
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteIndia
- Study dates
- 4 Apr 2017to 2 Dec 2019
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients of age 18-65 years
- BMI > 35 kg/m2
- Either sex
- ASA physical status II \& III
- Undergoing laparoscopic/ robotic bariatric surgery
Who cannot join
- Uncompensated cardiovascular disease (e.g. uncontrolled hypertension, atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance, diastolic dysfunction)
- Hepato-renal insufficiency
- Uncontrolled endocrinology disease (e.g. diabetes mellitus, hypothyroidism)
- Known allergy/hypersensitivity to the study drug
- Pulmonary dysfunction (obstructive/restrictive lung disease)
- Acute/chronic drug dependence/substance abuse
- Requirement of postoperative ventilation
- Refusal to informed consent
Trial locations and contacts
1 site in 1 country.
India1 site
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, 110060
About this study
Official title: Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Obese Patients Undergoing Bariatric Surgery: A Comparative Randomized Analysis of Recovery Profile
Complete recovery from anaesthesia is absolutely desirable in the obese patients to avoid postoperative airway, oxygen ventilation or sleep apnea related complications. Over the years, Desflurane has emerged as the anaesthetic agent of choice for maintenance of anaesthesia in obese patients for its efficient elimination profile and ability to facilitate early recovery from anaesthesia. Alternatively, Propofol is a commonly used intravenous anesthetic agent administered as a part of total intravenous anesthesia (TIVA) regimen. However, it is a lipid soluble drug and there are concerns that it may accumulate in obese patients due to their increased proportion of body fat Therefore, Propofol TIVA is likely to result in a prolonged duration of action and consequently, delayed emergence from anaesthesia and a protracted recovery time. A recent advance in the delivery of Propofol to the patient is the development of computer-controlled anesthesia delivery systems. These devices deliver Propofol based on feedback from patient's frontal cortex electrical activity as determined by monitoring bispectral index (BIS). Evaluation of anesthesia delivery by these systems has shown that Propofol and maintain depth of anesthesia with far more precision as compared to manual/simple infusion administration. This, in turn, holds promise that recovery from Propofol anaesthesia can also be favourable in the obese patients. An indigenously developed computer-controlled anesthesia delivery sytem is the closed loop anaesthesia delivery system (CLADS), which has been extensively evaluated in patients belonging to different surgical settings. The evidence generated with Propofol anaesthesia delivered by CLADS has shown significant improvement in recovery outcome.The performance of CLADS has not yet been evaluated in obese surgical patients. We hypothesise that in the obese patients undergoing bariatric surgery, automated delivery of Propofol using CLADS would allow precision control of anaesthesia depth, intra-operative haemodynamics, and rapid recovery from anaesthesia. We plan to conduct a randomised controlled investigation to compare patient recovery profile following Desflurane anaesthesia versus CLADS empowered Propofol anaesthesia.
Read the detailed description
After Institutional Ethics Committee approval and written informed consent, forty-participants (20 per group) aged 18-65 years, ASA physical status I/III, BMI >35-kg/m2, of either sex, and undergoing laparoscopic/robotic bariatric surgery (sleeve gastrectomy or gastric bypass) will be included in this single center (Sir Ganga Ram Hospital, New Delhi-110060, India) prospective, double-blinded, two-arm, randomised controlled study.
The patients who qualify inclusion criteria and consent for recruitment will be randomly divided into one of the two groups:
Group-1 [CLADS Group, n=20]: Anaesthesia will be induced and maintained with Propofol administered using the automated CLADS.
Group-2 [Desflurane Group, n=20]: Anaesthesia will be induced with Propofol administered using the automated CLADS and will be maintained with Desflurane.
Sample-size Estimation
In a previous study, the time-to-eye opening with Desflurane and Propofol was 4.2 minutes and 10.7 minutes, respectively. Based on above, a samples size of 15-patients will be required per group to provide 90% power with a bilateral α-risk value of 0.05 to posit a significant difference in time-to-eye opening. We plan to recruit a total of 40-patients to cover up for unanticipated losses after the recruitment.
Randomization, Allocation Concealment
The patients will be randomly allocated to one of the two groups based on a computer-generated random number table (url:stattrek.com/statistics/random-number-generator.aspx). Randomization sequence concealment will include opaque-sealed envelopes with alphabetic codes whose distribution will be in control of an independent analyst. The envelopes will be opened; patient's data-slip will be pasted on them, and will be sent back to the control analyst.
Blinding Strategy
The attending anaesthesiologist will not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. However, the postoperative patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.
Management of Anesthesia
Two peripheral venous lines (18G/20G catheter) will be secured. Standard monitoring (EKG, NIBP, pulse oximeter, EtCO2) will be applied. A BIS sensor (Covidien IIc, Mansfield, USA) will be applied over the patient's forehead according to manufacturer's instruction prior to induction of anaesthesia for monitoring depth of anaesthesia. The BIS monitoring module (Model DSC-XP, Aspect medical system, USA) will facilitate monitoring of anaesthesia depth.
Anaesthesia Technique
All the patients will be administered pre-induction fentanyl-citrate analgesia as per a predefined strategy (total 2-µg/kg IV: 1-µg/kg at 0 minute and 3-minute time point). Pre-oxygenation will be initiated at 3-minute time point or prior to that if there is a fall in oxygen saturation (< 94 percent). In both the groups, at 6-minute time point, anesthesia will be induced with Propofol administered by CLADS. In both the groups CLADS will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. After induction of anesthesia, atracurium besylate 0.05-mg/kg will be administered for skeletal muscle relaxation to facilitate tracheal intubation. Ventilator settings of CMV, tracheal tube size [7.5-mm I.D (male), 6.5-mm I.D (female)], and breathing circuit (circle-CO2 absorber system) will be the standardized in all the patients. Thereafter, the patients in the CLADS group will receive anaesthesia maintenance with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients. The patients in Desflurane group will receive anaesthesia maintenance with Desflurane dial concentration titrated to maintain a BIS of 50-55 in all the patients. Oxygen-air mixture (FiO2 0.50) will be used for ventilation in both the groups.
In addition, starting post-intubation, all the patients will receive 1.0-µg/kg/hr fentanyl infusion for intraoperative analgesia. Intraoperative muscle relaxation will be maintained using atracurium boluses controlled by train-of-four response on peripheral neuromuscular monitor (Infinity TridentNMT Smartpod, Draeger Medical Systems, Inc Telford, USA).
Thirty minutes before the end of surgery, non-opioid analgesics, such as paracetamol 1-gm, and tramadol 100-mg will be administered to the patient. The Propofol or Desflurane delivery will be stopped at the point of completion of skin closure. Residual neuromuscular blockade (assessed with train-of-four response) will be reversed with neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg).
Thirty minutes before the end of surgery, non-opioid analgesics, such as paracetamol 1-gm, and tramadol 100-mg will be administered to the patient. The Propofol or Desflurane delivery will be stopped at the point of completion of skin closure. Residual neuromuscular blockade (assessed with train-of-four response) will be reversed with neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg).
- Conditions
- Anesthesia; Bariatric Surgery
- Being tested
- Propofol, Desflurane
- Keywords
- propofol, CLADS, Desflurane, Obesity
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PropofolDrug
Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
DesfluraneDrug
Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
| Study group | Role | What they receive |
|---|---|---|
| CLADS group | Active comparator | Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients. Receives: Drug: Propofol |
| Desflurane group | Active comparator | Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients Receives: Drug: Propofol; Drug: Desflurane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Early Recovery
Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted
Measured: From end of anaesthesia till 20-minutes postoperatively
Early Recovery
Time taken for tracheal extubation after discontinuation of anaesthesia will be noted
Measured: From end of anaesthesia till 30-minutes postoperatively
Early recovery
Ability of the patient to comprehend instructions for shifting himself/herself from the OR table to the transport bed will be assessed using a 4-point scale
Measured: From end of anaesthesia till 30-minutes postoperatively
Intermediate recovery
Time taken to achieve a modified Aldrete score of 9 or 10
Measured: From end of anaesthesia till 180-minutes postoperatively
Secondary outcomes (7)
Changes in intra-operative heart rate (beats per minute)
Comparison of intra-operative heart rate between both the arms will be done
Measured: From beginning of anesthesia (0-hours, baseline) till 6 hours intra-operatively
Change in Intra-operative blood pressure - systolic , diastolic, and mean (mmHg)
Comparison of intra-operative blood pressure- systolic, diastolic, and mean between both the arms will be done
Measured: From beginning of anesthesia (0-hours, baseline) till 6 hours intraoperatively
Postoperative Sedation
Will be assessed using Modified Observer's assessment of alertness/sedation scale (OASS)
Measured: From end of anaesthesia till 24-hours postoperatively
Postoperative Nausea and Vomiting
Will be assessed using PONV Scale
Measured: From end of anaesthesia till 24-hours postoperatively
Postoperative Analgeisa
Will be assessed using 10-point Visual Analogue Scale (VAS) Score
Measured: From end of anaesthesia till 24-hours postoperatively
Patient Satisfaction
Will be assessed using a 10-point numeric rating scale
Measured: From end of anaesthesia till 24-hours postoperatively
Anesthesia Depth Consistency
Determined by the percentage of the total anaesthesia time in which the BIS scores remain within a score of 10% of the target BIS (i.e. BIS-50) and Varvel criteria parameters; median performance error (MDP), median absolute performance error (MDAPE), wobble and global score
Measured: From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2017
- Study start4 Apr 2017
- Primary completion2 Dec 2019
- Study completion2 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anesthesia; Bariatric SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 40 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic/robotic bariatric surgery (sleeve gastrectomy, Rouxen- Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 20 patients each. Group-1 \[CLADS Group, n=20\]: Anaesthesia will be induced and maintained with Propofol administered using the automated CLADS. Group-2 \[Desflurane Group, n=20\]: Anaesthesia will be induced with Propofol administered using the automated CLADS and will be maintained with Desflurane.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Nitin Sethi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr Nitin Sethi, Sir Ganga Ram Hospital
- Investigators
- Goverdhan D Puri, MD, PhD, Study chair, Post Graduate Institute of Medical Education & Research, Chandigarh, IndiaJayashree Sood, MD,FFRCA, Study director, Sir Ganga Ram Hospital, New Delhi, INDIAAmitabh Dutta, MD, Principal investigator, Sir Ganga Ram Hospital, New Delhi, INDIANitin Sethi, DNB, Principal investigator, Sir Ganga Ram Hospital, New Delhi, INDIA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03099616
- Sponsor's protocol ID
- EC/01/17/1105
- Status last verified
- Dec 2019
- First submitted
- 28 Mar 2017
- Last updated
- 23 Dec 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Obese Patients Undergoing Bariatric Surgery: A Comparative Randomized Analysis of Recovery Profile
- ClinicalTrials.gov ID
- NCT03099616
- Acronym / sponsor ID
- EC/01/17/1105
- Conditions
- Anesthesia; Bariatric Surgery
- Keywords
- propofol, CLADS, Desflurane, Obesity
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Dr Nitin SethiUniversity, hospital or other
- Study start
- 4 Apr 2017 (actual)
- Primary completion
- 2 Dec 2019 (actual)
- Study completion
- 2 Dec 2019 (actual)
- First posted
- 4 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Complete recovery from anaesthesia is absolutely desirable in the obese patients to avoid postoperative airway, oxygen ventilation or sleep apnea related complications. Over the years, Desflurane has emerged as the anaesthetic agent of choice for maintenance of anaesthesia in obese patients for its efficient elimination profile and ability to facilitate early recovery from anaesthesia. Alternatively, Propofol is a commonly used intravenous anesthetic agent administered as a part of total intravenous anesthesia (TIVA) regimen. However, it is a lipid soluble drug and there are concerns that it may accumulate in obese patients due to their increased proportion of body fat Therefore, Propofol TIVA is likely to result in a prolonged duration of action and consequently, delayed emergence from anaesthesia and a protracted recovery time. A recent advance in the delivery of Propofol to the patient is the development of computer-controlled anesthesia delivery systems. These devices deliver Propofol based on feedback from patient's frontal cortex electrical activity as determined by monitoring bispectral index (BIS). Evaluation of anesthesia delivery by these systems has shown that Propofol and maintain depth of anesthesia with far more precision as compared to manual/simple infusion administration. This, in turn, holds promise that recovery from Propofol anaesthesia can also be favourable in the obese patients. An indigenously developed computer-controlled anesthesia delivery sytem is the closed loop anaesthesia delivery system (CLADS), which has been extensively evaluated in patients belonging to different surgical settings. The evidence generated with Propofol anaesthesia delivered by CLADS has shown significant improvement in recovery outcome.The performance of CLADS has not yet been evaluated in obese surgical patients. We hypothesise that in the obese patients undergoing bariatric surgery, automated delivery of Propofol using CLADS would allow precision control of anaesthesia depth, intra-operative haemodynamics, and rapid recovery from anaesthesia. We plan to conduct a randomised controlled investigation to compare patient recovery profile following Desflurane anaesthesia versus CLADS empowered Propofol anaesthesia.
Detailed description
After Institutional Ethics Committee approval and written informed consent, forty-participants (20 per group) aged 18-65 years, ASA physical status I/III, BMI >35-kg/m2, of either sex, and undergoing laparoscopic/robotic bariatric surgery (sleeve gastrectomy or gastric bypass) will be included in this single center (Sir Ganga Ram Hospital, New Delhi-110060, India) prospective, double-blinded, two-arm, randomised controlled study.
The patients who qualify inclusion criteria and consent for recruitment will be randomly divided into one of the two groups:
Group-1 [CLADS Group, n=20]: Anaesthesia will be induced and maintained with Propofol administered using the automated CLADS.
Group-2 [Desflurane Group, n=20]: Anaesthesia will be induced with Propofol administered using the automated CLADS and will be maintained with Desflurane.
Sample-size Estimation
In a previous study, the time-to-eye opening with Desflurane and Propofol was 4.2 minutes and 10.7 minutes, respectively. Based on above, a samples size of 15-patients will be required per group to provide 90% power with a bilateral α-risk value of 0.05 to posit a significant difference in time-to-eye opening. We plan to recruit a total of 40-patients to cover up for unanticipated losses after the recruitment.
Randomization, Allocation Concealment
The patients will be randomly allocated to one of the two groups based on a computer-generated random number table (url:stattrek.com/statistics/random-number-generator.aspx). Randomization sequence concealment will include opaque-sealed envelopes with alphabetic codes whose distribution will be in control of an independent analyst. The envelopes will be opened; patient's data-slip will be pasted on them, and will be sent back to the control analyst.
Blinding Strategy
The attending anaesthesiologist will not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. However, the postoperative patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.
Management of Anesthesia
Two peripheral venous lines (18G/20G catheter) will be secured. Standard monitoring (EKG, NIBP, pulse oximeter, EtCO2) will be applied. A BIS sensor (Covidien IIc, Mansfield, USA) will be applied over the patient's forehead according to manufacturer's instruction prior to induction of anaesthesia for monitoring depth of anaesthesia. The BIS monitoring module (Model DSC-XP, Aspect medical system, USA) will facilitate monitoring of anaesthesia depth.
Anaesthesia Technique
All the patients will be administered pre-induction fentanyl-citrate analgesia as per a predefined strategy (total 2-µg/kg IV: 1-µg/kg at 0 minute and 3-minute time point). Pre-oxygenation will be initiated at 3-minute time point or prior to that if there is a fall in oxygen saturation (< 94 percent). In both the groups, at 6-minute time point, anesthesia will be induced with Propofol administered by CLADS. In both the groups CLADS will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. After induction of anesthesia, atracurium besylate 0.05-mg/kg will be administered for skeletal muscle relaxation to facilitate tracheal intubation. Ventilator settings of CMV, tracheal tube size [7.5-mm I.D (male), 6.5-mm I.D (female)], and breathing circuit (circle-CO2 absorber system) will be the standardized in all the patients. Thereafter, the patients in the CLADS group will receive anaesthesia maintenance with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients. The patients in Desflurane group will receive anaesthesia maintenance with Desflurane dial concentration titrated to maintain a BIS of 50-55 in all the patients. Oxygen-air mixture (FiO2 0.50) will be used for ventilation in both the groups.
In addition, starting post-intubation, all the patients will receive 1.0-µg/kg/hr fentanyl infusion for intraoperative analgesia. Intraoperative muscle relaxation will be maintained using atracurium boluses controlled by train-of-four response on peripheral neuromuscular monitor (Infinity TridentNMT Smartpod, Draeger Medical Systems, Inc Telford, USA).
Thirty minutes before the end of surgery, non-opioid analgesics, such as paracetamol 1-gm, and tramadol 100-mg will be administered to the patient. The Propofol or Desflurane delivery will be stopped at the point of completion of skin closure. Residual neuromuscular blockade (assessed with train-of-four response) will be reversed with neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg).
Thirty minutes before the end of surgery, non-opioid analgesics, such as paracetamol 1-gm, and tramadol 100-mg will be administered to the patient. The Propofol or Desflurane delivery will be stopped at the point of completion of skin closure. Residual neuromuscular blockade (assessed with train-of-four response) will be reversed with neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- 40 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic/robotic bariatric surgery (sleeve gastrectomy, Rouxen- Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 20 patients each. Group-1 [CLADS Group, n=20]: Anaesthesia will be induced and maintained with Propofol administered using the automated CLADS. Group-2 [Desflurane Group, n=20]: Anaesthesia will be induced with Propofol administered using the automated CLADS and will be maintained with Desflurane.
| Arm | Type | Receives |
|---|---|---|
| CLADS group | Active comparator | Drug: PropofolAnesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients. |
| Desflurane group | Active comparator | Drug: Propofol, Drug: DesfluraneAnesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients of age 18-65 years
- BMI > 35 kg/m2
- Either sex
- ASA physical status II \& III
- Undergoing laparoscopic/ robotic bariatric surgery
Key exclusion criteria (8 listed)
- Uncompensated cardiovascular disease (e.g. uncontrolled hypertension, atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance, diastolic dysfunction)
- Hepato-renal insufficiency
- Uncontrolled endocrinology disease (e.g. diabetes mellitus, hypothyroidism)
- Known allergy/hypersensitivity to the study drug
- Pulmonary dysfunction (obstructive/restrictive lung disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PropofolPropofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient. | Drug | CLADS group, Desflurane group |
| DesfluraneDesflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients. | Drug | Desflurane group |
Primary outcome
Early Recovery
Time frame: From end of anaesthesia till 20-minutes postoperatively
Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted
Early Recovery
Time frame: From end of anaesthesia till 30-minutes postoperatively
Time taken for tracheal extubation after discontinuation of anaesthesia will be noted
Early recovery
Time frame: From end of anaesthesia till 30-minutes postoperatively
Ability of the patient to comprehend instructions for shifting himself/herself from the OR table to the transport bed will be assessed using a 4-point scale
Intermediate recovery
Time frame: From end of anaesthesia till 180-minutes postoperatively
Time taken to achieve a modified Aldrete score of 9 or 10
7 secondary outcomes
Changes in intra-operative heart rate (beats per minute)
Time frame: From beginning of anesthesia (0-hours, baseline) till 6 hours intra-operatively
Change in Intra-operative blood pressure - systolic , diastolic, and mean (mmHg)
Time frame: From beginning of anesthesia (0-hours, baseline) till 6 hours intraoperatively
Postoperative Sedation
Time frame: From end of anaesthesia till 24-hours postoperatively
Postoperative Nausea and Vomiting
Time frame: From end of anaesthesia till 24-hours postoperatively
Postoperative Analgeisa
Time frame: From end of anaesthesia till 24-hours postoperatively
Patient Satisfaction
Time frame: From end of anaesthesia till 24-hours postoperatively
Anesthesia Depth Consistency
Time frame: From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively]
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Anesthesia; Bariatric Surgery
Not yet recruiting
Comparison of Intensive and Conservative NOL®-Guided Analgesia Strategies During Opioid-free Anesthesia
Anesthesia, Bariatric Surgery (Gastric Bypass)
Not yet recruiting
Comparison of Paragastric Nerve Block and Erector Spinae Plane Block on Postoperative Pain After Sleeve Gastrectomy
Obesity Postoperative Pain, Obesity Morbid Obesity Postoperative Pain
RecruitingObservational study
Postoperative Nausea, Vomiting and Pain After Bariatric Surgery - a National Registry Study
Postoperative Nausea and Vomiting, Postoperative Pain
Not yet recruitingPhase 4
Swap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery
Obesity, Bariatric Surgery
Active, not recruiting
Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids
Opioid Use, Unspecified, Bariatric Surgery Candidate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Goverdhan D Puri, MD, PhD study chair
Post Graduate Institute of Medical Education & Research, Chandigarh, India
Jayashree Sood, MD,FFRCA study director
Sir Ganga Ram Hospital, New Delhi, INDIA
Amitabh Dutta, MD principal investigator
Sir Ganga Ram Hospital, New Delhi, INDIA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Propofol and Desflurane in people with Anesthesia; Bariatric Surgery, run by Dr Nitin Sethi at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Early Recovery (time frame: From end of anaesthesia till 20-minutes postoperatively). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2019.